Comparison 5. EGFR inhibitors in KRAS unselected participants.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Progression‐free survival	2		Hazard Ratio (Fixed, 95% CI)	0.70 [0.62, 0.78]
2 Overall survival	2		Hazard Ratio (Fixed, 95% CI)	0.96 [0.84, 1.09]
3 Tumour response rate	2	1372	Odds Ratio (M‐H, Fixed, 95% CI)	3.70 [2.49, 5.49]
4 Overall grade 3/4 toxicity	1	1267	Odds Ratio (M‐H, Fixed, 95% CI)	2.12 [1.69, 2.65]
5 Grade 3/4 diarrhoea	2	1341	Odds Ratio (M‐H, Fixed, 95% CI)	2.08 [1.59, 2.71]
6 Grade 3/4 rash	2	1341	Odds Ratio (M‐H, Fixed, 95% CI)	39.89 [7.82, 203.35]
7 Grade 3/4 neutropenia	2	1341	Odds Ratio (M‐H, Fixed, 95% CI)	1.39 [1.08, 1.78]